Mylan said
earlier it would launch the first generic version of EpiPen for
$300, half the price of the branded product, in the drugmaker's
second step in less than a week to counter a backlash over the
product's steep price.
Chaffetz and Cummings, the committee's chairman and ranking
member respectively, requested documents related to Mylan's
revenue from sales of EpiPens since 2007, manufacturing costs
and the amount the company receives from federal health care
programs.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.

|
|